Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant weighs ≥ 40 kg (88 lb)~* Participant has symptoms of Over Active Bladder (OAB) (frequency and urgency) with urinary incontinence for a period of at least 6 months immediately prior to screening.~Exclusion Criteria:~* Participant has symptoms of OAB due to any known neurological reason (eg, spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc.)~* Participant has received pharmacologic therapy to treat symptoms of OAB, including nocturia, within 7 days of the start of the screening period procedures~* Participant uses clean intermittent catheterization (CIC) or indwelling catheter to manage urinary incontinence~* Participant has been treated with any intravesical pharmacologic agent (eg, capsaicin, resiniferatoxin) within 12 months of Day 1~* Participant has had previous or current botulinum toxin therapy of any serotype for any urological condition~* Participant has had previous or current botulinum toxin therapy of any serotype for any non-urological condition within 12 weeks of Day 1~* Participant has been immunized for any botulinum toxin serotype~* Participant has history or evidence of any pelvic or urological abnormalities, bladder surgery or disease, other than OAB, that may affect bladder function~* Participant has an active genital infection, other than genital warts, either concurrently or within 4 weeks prior to screening~* Participant has a history or current diagnosis of bladder cancer or other urothelial malignancy~* Participant is male with previous or current diagnosis of prostate cancer~* Participant has a history of 2 or more urinary tract infections (UTIs) within 6 months of Day 1 or is taking prophylactic antibiotics to prevent chronic UTIs~* Participant has current or previous uninvestigated hematuria~* Participant has hemophilia, or other clotting factor deficiencies, or disorders that cause bleeding diathesis~* Participant cannot withhold any antiplatelet, anticoagulant therapy or medications with anticoagulant effects for 3 days prior to Day 1~* Participant has a known allergy or sensitivity to any botulinum toxin preparation~* Participant has any medical condition that may put him/her at increased risk with exposure to BOTOX® including diagnosed myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis~* Participant has current swallowing or breathing difficulties.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BOTOX® 100 U/BOTOX® 100 U (Type: ACTIVE_COMPARATOR): BOTOX® (onabotulinumtoxinA) 100 U injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
- Placebo/BOTOX® 100 U (Type: PLACEBO_COMPARATOR): Placebo (saline) injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete